Q-omics provides the consensus-scored NUDT19P3 profile across patient tissues and cancer cell-line models. NUDT19P3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, NUDT19P3 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, NUDT19P3 RNA expression shows 12,271 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, LUSC, and TGCT as cancer lineages where NUDT19P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT19P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT19P3 survival associations across molecular data types. NUDT19P3 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT19P3 RNA expression–survival associations across cancer types. High NUDT19P3 expression shows unfavorable associations in ACC, but favorable associations in READ, UCS, COAD, LAML and BRCA. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify READ as the clearest survival context for NUDT19P3 RNA expression.
This table summarizes NUDT19P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NUDT19P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT19P3 shows lower tumor expression in BRCA and HNSC and higher tumor expression in LUSC, KIRP, COAD and UCEC. The LUSC box plot shows higher NUDT19P3 RNA expression in tumor versus normal tissue (log2 FC = +0.386, t-test p = .002).
This table shows molecular features associated with NUDT19P3 in patient tissues and cancer cell lines. In patient samples, NUDT19P3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
